ArticleEJNMMI radiopharmacy and chemistry2023
Imaging of fibrogenesis in the liver by [
Article in EJNMMI radiopharmacy and chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 21 citations in OpenAlex.
- Biodistribution and radiation dosimetry of the PDGFRβ targeting PET tracer [European journal of nuclear medicine and molecular imaging · 2026Article
- Increased affinity by dimerization of radiolabeled Affibody molecule ATH001 targeting PDGFRβ.EJNMMI radiopharmacy and chemistry · 2026Article
- [ACS omega · 2026Article
- A novelEJNMMI radiopharmacy and chemistry · 2026Article
- PDGFRß targeted positron emission tomography as a non-invasive biomarker for activated hepatic stellate cells: lasts steps before clinical translation.EJNMMI radiopharmacy and chemistry · 2025Article
- Ga-68-Labeled Affibody Molecule-Based Radiopharmaceutical Targeting Platelet Derived Growth Factor Receptor Beta for Detection of Active Fibrosis in Patients with Myocardial Infarction.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Fibrotic Disease: from Signaling Pathways and Biomarkers to Molecular Imaging.Molecular imaging and biology · 2025Review
- Platelet-derived growth factor receptor-β as a non-invasive biomarker for liver fibrosis prediction in Egyptian diabetic patients with metabolic-associated fatty liver disease.BMC gastroenterology · 2025Article
- PET imaging of platelet derived growth factor receptor β in lung fibrosis.EJNMMI radiopharmacy and chemistry · 2025Article
- Review
- Synthesis and preclinical evaluation of gastrin releasing peptide receptor antagonist [EJNMMI radiopharmacy and chemistry · 2025Article
- Non-invasive diagnosis of liver fibrosis via MRI using targeted gadolinium-based nanoparticles.European journal of nuclear medicine and molecular imaging · 2024Article
- Preclinical targeting of liver fibrosis with aEuropean journal of nuclear medicine and molecular imaging · 2024Article
- Non-invasive PET imaging of liver fibrogenesis using a RESCA-conjugated Affibody molecule.iScience · 2024Article
- Synthesis and evaluation of fluorine-18 labelled tetrazines as pre-targeting imaging agents for PET.EJNMMI radiopharmacy and chemistry · 2024Article
- Radiotracers for Imaging of Fibrosis: Advances during the Last Two Decades and Future Directions.Pharmaceuticals (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlatelet-derived growth factor receptor beta (PDGFRβ) is a receptor overexpressed on activated hepatic stellate cells (aHSCs). Positron emission tomography (PET) imaging of PDGFRβ could potentially allow the quantification of fibrogenesis in fibrotic livers. This study aims to evaluate a fluorine-18 radiolabeled Affibody molecule ([
resultsIn vitro specificity studies demonstrated that the trans-Cyclooctenes (TCO) conjugated Z09591 Affibody molecule had a picomolar affinity for human PDGFRβ. Biodistribution performed on healthy rats showed rapid clearance of [
conclusionsOur study highlights [18F]TZ-Z09591 as a specific tracer for fibrogenic cells in the fibrotic liver, thus offering the potential to assess fibrogenesis clearly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.